
Ask a doctor about a prescription for ACETYLCYSTEINE AUROVITAS 600 mg EFFERVSCENT TABLETS
Leaflet:information for the user
Acetylcysteine Aurovitas 600 mg effervescent tablets EFG
Read this leaflet carefully before starting to take this medicine,as it contains important information for you.
Contents of the leaflet
5 Conservation of Acetylcysteine Aurovitas
Acetylcysteine Aurovitas contains the active ingredient acetylcysteine, which liquefies the viscous mucus of the respiratory tract.
Acetylcysteine is used to expelmucus and relieve coughin cases of colds in adults.
Do not take Acetylcysteine Aurovitas
Warnings and precautions
Consult your doctor or pharmacist before starting to take acetylcysteine.
If you have bronchial asthma, acetylcysteine should be taken under close medical supervision because it can cause narrowing of the airways (bronchospasm). If you experience such symptoms, stop using acetylcysteine immediately.
If you have or have had a peptic ulcer, as acetylcysteine can irritate the gastric lining. Especially if you use other medications that irritate the gastric lining.
Very rarely, serious skin reactions, such as Stevens-Johnson syndrome and Lyell syndrome, have been reported in relation to the use of acetylcysteine. If new changes in the skin and mucous membranes occur, consult a doctor without delay and stop using acetylcysteine.
Long-term treatment should be avoided in these patients, as this medicine influences histamine metabolism and may cause intolerance symptoms (e.g., headache, nasal discharge, itching).
Mucolytics can obstruct the airways of children under 2 years of age due to their characteristics and limited ability to cough up sputum. Therefore, children under 2 years of age should not use mucolytics.
Other medicines and Acetylcysteine Aurovitas
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medicine.
This applies particularly to:
The combined use of acetylcysteine with cough suppressants can cause a dangerous accumulation of secretions due to the reduction of the cough reflex. A particularly careful diagnosis is required for this combined treatment. It is essential that you ask your doctor before using this combination.
Experimental studies show evidence of a weakening effect of antibiotics (tetracyclines, aminoglycosides, penicillins) due to acetylcysteine. For safety reasons, antibiotics should be taken separately and with an interval of at least 2 hours. This does not apply to medications with the active ingredients cefixime or loracarbef. These can be taken with acetylcysteine at the same time.
Your doctor will monitor if you have low blood pressure, which could be severe and could be detected by a headache.
When used at the same time as carbamazepine, the effects of carbamazepine may be reduced due to the decrease in plasma levels.
Laboratory tests
Tell your doctor that you are taking acetylcysteine if you need a test for the following:
may affect the determination of:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
Since there is not enough experience with the use of this medicine in pregnant women, you can only use acetylcysteine during pregnancy if your doctor considers it absolutely necessary.
Breast-feeding
No information is available on the excretion of acetylcysteine in breast milk. You should
therefore use this medicine during breast-feeding only if your doctor considers it absolutely necessary.
Driving and using machines
the influence of this on the ability to drive or use machines is not known.
Acetylcysteine Aurovitas contains lactose
If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Acetylcysteine Aurovitas contains aspartame
This medicine contains 15 mg of aspartame in each effervescent tablet.
Aspartame (E951) contains a source of phenylalanine, which may be harmful in case of phenylketonuria (PKU), a rare genetic disease in which phenylalanine accumulates because the body is unable to eliminate it properly.
Acetylcysteine Aurovitas contains sodium
This medicine contains 65.71 mg of sodium (main component of table/cooking salt) in each effervescent tablet. This is equivalent to 3.29% of the maximum recommended daily intake of sodium for an adult.
Follow the instructions for administration of the medicine contained in this leaflet or as indicated by your doctor, pharmacist, or nurse. In case of doubt, ask your doctor or pharmacist.
The recommended dose, unless your doctor prescribes otherwise, is:
Adults from 18 years: 1 effervescent tablet once a day.
Method of administration
Dissolve the effervescent tablet in half a glass of water and drink the solution immediately.
It is recommended that patients who have difficulty expelling phlegm (elderly and debilitated patients) take the effervescent tablet in the morning.
Duration of treatment
Do not use this medicine for more than 14 days without consulting your doctor.
If your symptoms worsen or do not improve after 4-5 days, you should consult your doctor.
If you take more Acetylcysteine Aurovitas than you should
In case of overdose, stomach and intestinal irritations, such as abdominal pain, nausea, vomiting, diarrhea, may occur.
So far, no serious side effects or symptoms of intoxication have been observed, even in the case of massive overdose. However, if an overdose with acetylcysteine is suspected, please inform your doctor.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount ingested
If you forget to take Acetylcysteine Aurovitas
Do not take a double dose to make up for missed doses. Simply take your next dose at the usual time.
If you have any other doubts about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone gets them.
Stop taking Acetylcysteine Aurovitas and contact your doctor if signs of allergy or a serious skin reaction appear.
Uncommon (may affect up to 1 in 100 people)
Very rare (may affect up to 1 in 10,000 people)
Other possible side effects may occur with the following frequencies:
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Frequency not known (frequency cannot be estimated from available data)
Reporting of side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet. You can also report them directly through the Spanish Medicines Monitoring System: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the strips and the package after CAD. The expiration date is the last day of the month indicated.
Store below 30°C.
Keep in the original packaging to protect it from light.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Acetylcysteine Aurovitas
Each effervescent tablet contains 600 mg of acetylcysteine.
Appearance and package contents of the product
Effervescent tablets.
Acetylcysteine Aurovitas 600 mg effervescent tablets EFG:
White, flat, round, and beveled tablets.
Acetylcysteine Aurovitas 600 mg effervescent tablets are available in strips (composite film - PAPER/AL/PE).
Package sizes:
Strips: 10, 20, 30, and 60 effervescent tablets.
Not all package sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Manufacturer
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
O
Generis Farmacêutica, S.A.
Rua João de Deus, 19
2700-487 Amadora
Portugal
This medicine is authorized in the Member States of the European Economic Area under the following names:
Belgium: Acetylcysteine AB 600 mg bruistabletten / comprimés effervescents / Brausetabletten
Spain: Acetilcisteína Aurovitas 600mg comprimidos efervescentes EFG
Italy: Acetilcisteina Aurobindo
Netherlands: Acetylcysteine Auro 600mg, bruistabletten
Poland: Aceflucil
Portugal: Acetilcisteína Generis
Date of last revision of this leaflet:05/2022
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ACETYLCYSTEINE AUROVITAS 600 mg EFFERVSCENT TABLETS – subject to medical assessment and local rules.